Fluphenazine Elixir Rx
Generic Name and Formulations:
Fluphenazine HCl 0.5mg/mL; alcohol 14%.
Various generic manufacturers
Indications for Fluphenazine Elixir:
Initially: 2.5–10mg daily in 3–4 divided doses; max 40mg daily.
Initially 1–2.5mg daily in 3–4 divided doses; max 40mg daily.
Coma. CNS or bone marrow depression. Liver disease. Subcortical brain damage. Blood dyscrasias.
Cardiovascular or renal disease. Pheochromocytoma. Seizures. Glaucoma. History of breast cancer. Exposure to extreme heat or organophosphates. Gradually reduce to lowest effective maintenance dose. Monitor blood, liver, renal, and ocular function. Mental retardation. Surgery. Pregnancy. Nursing mothers.
Potentiates anticholinergics, CNS depression with alcohol and other CNS depressants; both drugs with propranolol. Antagonized by anticholinergics. Decreased guanethidine effects. May cause false (+) pregnancy test.
Drowsiness, anticholinergic and other autonomic effects, insomnia, restlessness, rash, photosensitivity, tardive dyskinesia, blood dyscrasias, jaundice, pneumonia, hypertension, retinopathy, lowered seizure threshold, extrapyramidal reactions, neuroleptic malignant syndrome, weight changes, endocrine effects.
Formerly known under the brand names Prolixin (tabs, concentrate, elixir, inj); Permitil (tabs, concentrate); Prolixin Decanoate (decanoate inj).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|